| 日 | 月 | 火 | 水 | 木 | 金 | 土 |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | ||
| 6 | 7 | 8 | 9 | 10 | 11 | 12 |
| 13 | 14 | 15 | 16 | 17 | 18 | 19 |
| 20 | 21 | 22 | 23 | 24 | 25 | 26 |
| 27 | 28 | 29 | 30 | 31 |
< レクチャーmemo 関節リウマチ治療にお... | メイン | レクチャーメモ（ステロイドと肺炎リスク）... >
NY TIMES By DENISE GRADY and ANDREW POLLACK
Published: July 27, 2007
・Targeted Genetics
・"not known whether the treatment had a role or the death was a coincidence. The agency said the timing was cause for concern"
・"The company had used the same type of virus (adeno-associated virus) [アデノ随伴ウイルスベクター] to carry various genes into more than 500 patients and had not seen similar problems. “These patients are all on several different medications,” she said. “They certainly have disease characteristics.”
・"Dr. Friedmann said the AAV system used in the experiment was widely regarded as safe. But, “We’ll probably come to learn it does some harmful things in some settings.”
--
tgAAC94 = an intra-articular-injected recombinant adeno-associated virus (AAV) vector that encodes a soluble form of the TNF-alpha receptor (TNFR:Fc).最初の61例のdose escalationの安全性は2007年EULARで発表されている。
固定リンク | コメント (0) | トラックバック (0)
コメント
コメントはまだありません。コメントを書く